NewsBenzingaJazz Pharmaceuticals、Actio Biosciences買収に伴い取得したIPR&D費用として税引前7億5,500万ドルを計上見込み――2026年第3四半期のGAAPおよび調整後EPSにそれぞれ11.00ドルのマイナス影響を見込む Jazz Pharmaceuticals、Actio Biosciences買収に伴い取得したIPR&D費用として税引前7億5,500万ドルを計上見込み――2026年第3四半期のGAAPおよび調整後EPSにそれぞれ11.00ドルのマイナス影響を見込む Benzinga 2026.10.26 20:29 (GMT+0) Open on Benzinga Other news CalPERS Discloses $37.1 Million Stake in Strategy Scammers Used Musk Deepfake Video to Defraud; Coinbase AI System Blocked $4.7 Million JPMorgan Is Developing AI Agent Trading Without Human Involvement Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense
Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle
Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws
Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense